Increased expression of annexin I is associated with drug-resistance in nasopharyngeal carcinoma and other solid tumors.
Adjuvant chemotherapy alongside radiotherapy is one of the effective therapies in nasopharyngeal carcinoma (NPC) treatment. However, the appearance of drug resistance is a major obstacle for anti-cancer chemotherapy and often causes failure of the chemotherapy. In this study, a drug-resistant gene annexin I (ANX-I) was identified by comparing differentially expressed proteins between a cisplatin (CDDP)-resistant NPC cell line CNE2-CDDP and parental CNE2 cells using 2-DE. When ANX-I was transfected into CNE2 cells, the CDDP resistance of CNE2 cells was dramatically increased. The drug-resistant ability of ANX-I was demonstrated by both in vitro and in vivo assays. The association of ANX-I expression with clinical features was also investigated. Increased expression of ANX-I was significantly associated with disease relapse in NPC (p<0.05). In breast and gastric cancer, increased expression of ANX-I was significantly associated with drug resistance (p<0.001) and poor prognosis (p<0.001), respectively. Taken together, our findings suggest that ANX-I plays an important role in drug resistance.
Department of Clinical Oncology, The University of Hong Kong, Pokfulam, Hong Kong, P. R. China.
Betty H Y
BH
Chow
Daniel T T
DT
Chua
Jonathan S T
JS
Sham
Min-Yue
MY
Zhang
Louis W C
LW
Chow
Jiong
J
Bi
Ning-Fang
NF
Ma
Dan
D
Xie
Wings T Y
WT
Loo
Jackie M W
JM
Fung
Li
L
Fu
Xin-Yuan
XY
Guan